Cargando…
Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation
In favor of their outgrowth, cancer cells must resist immune surveillance and edit the immune response. Cancer immunoediting is characterized by fundamental changes in the cellular composition and the inflammatory cytokine profiles in the microenvironment of the primary tumor and metastatic niches,...
Autores principales: | Greil, Richard, Hutterer, Evelyn, Hartmann, Tanja Nicole, Pleyer, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244547/ https://www.ncbi.nlm.nih.gov/pubmed/28100240 http://dx.doi.org/10.1186/s12964-016-0155-9 |
Ejemplares similares
-
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation
por: Wolff, Florian, et al.
Publicado: (2017) -
Digging deep into “dirty” drugs – modulation of the methylation machinery
por: Pleyer, Lisa, et al.
Publicado: (2015) -
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
por: Huemer, Florian, et al.
Publicado: (2021) -
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
por: Gettinger, S. N., et al.
Publicado: (2018) -
Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)